Proven Novel Method to Curtail Covid-19 Pandemic, Long Covid, any Future Viral Pandemics, Including Influenza, Due to RNA/DNA Viruses Through Inactivation of their Naked RNA/DNA, and Hospital Acquired [Nosocomial] Infections

The main object of this research oriented experimental investigation is to evaluate the methods to totally inactivate the SARS-COV-2 and its newly developed variants, including their genetic material [naked RNA/DNA]. The viral naked RNA is referred to as RNA outside the body or integral structure of the virus. The United States Patent # 11,643,641 B2 was issued on May 9th, 2023, with a title “Prevention of Viral Transmission by Naked Genetic Material”. The research pertaining to this patent was initiated in the years 2020 and 2021 at which time the majority of the Corona Viral variants that were causing Covid-19 infection and Pandemic were: Alpha [B.1.1.7]; Beta [B.1.351]; and Delta [B.1.617.2] and several of their subvariants belonging to the SARS-CoV-2 viral lineage. Most of the experiments apparently were directed towards inactivating the above SARS-COV-2 variants. Due to continuous mutations encountered in the genome of the variants of the original SARS-COV-2 Corona Virus, several new variants were developed towards the end of the year 2021. Out of all the prior variants, Delta has more transmission rate as well as the dominant version of causing Covid-19. By mid-December of 2021 and early 2022, the new variant Omicron emerged onto the scene. According to several experts including CDC most of the original variants including Delta are now non-existent in the year 2023. The predominant variants and subvariants of the omicron became the major contributing factors to cause Covid-19 during the year 2023. Since our patent application was submitted on Feb 25, 2022, [Patent was issued on May 9, 2023], in all probability our field experiments must not have involved any attempts to check for the efficiency of our Novel procedure to inactivate the newly evolved Omicron and its variants and subvariants. Thus, this R&D project is specifically undertaken to check the efficacy of the Patented procedure outlined in the US Patent # 11,643,641 B2 on inactivating the Omicron variants evolved during the year 2023, [although earlier we have proved that Delta variants were inactivated], in an attempt to use it as an effective tool confidently to control and curtail the current and unforeseen future Pandemics. The laboratory studies conducted, using the saliva samples of the RT-PCR test positive SARSCoV- 2 infected persons, distinctly proved that the procedures outlined in US patent # 11,643,641 B2 are valid and extremely effective in inactivating the Omicron virus and its viral naked RNA, including denaturation of the viral nucleocapsid, spike, membrane, and envelope proteins. We have also confirmed that mechanical microbial vectors [which can also cause hospital acquired [Nosocomial] infections, which help to spread the viral particles including their naked RNA or DNA can also be totally inactivated using the novel Patented procedure outlined in the US patent # 11,643,641 B2. The details of which are outlined with explicit details in this research article.

The detailed sophisticated techniques were developed, for the first time, to study the effect of the naked viral DNA belonging to bacteriophage specific to bacterium Streptococcus thermophilus, to infect the host, propagate, and lyse the cells, without the aid of appendices such as head and tail structures, proving viral naked DNA by itself can also cause infection. Detailed pictorial illustrations are presented to show the mechanism of Covid-19 infection by the SARS-CoV-2 virus, and its naked RNA, with the aid of mechanical microbial vectors. Experimental proof is presented to show that the novel patented procedure [US Patent # 11,643,641 B2] can be effectively applied to control not only Covid-19 pandemic but also any future pandemics due to enveloped or non-enveloped RNA and/or DNA viruses. The patented procedure works irrespective of number of mutations involved in the mutants and sub mutants belonging to the lineage of the SARS-COV-2 virus, and for that matter any viral lineage, including but not limited to influenza virus etc.

Keywords:Naked RNA; Naked DNA; Long Covid; SARS-CoV-2; RNASE; DNASE; Covid-19; Delta and Omicron Variants; Hospital Acquired infections; Viral and Microbial Pandemics; Nosocomial Infections